How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?
  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?
  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

1.1 Pemigatinib is not recommended, within its anticipated marketing authorisation, for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after systemic therapy in adults.

1.2 This recommendation is not intended to affect treatment with pemigatinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Why the committee made these recommendations

Current treatment for advanced cholangiocarcinoma with an FGFR2 fusion or rearrangement that has progressed after systemic therapy is symptom control, with or without modified folinic acid, 5-fluorouracil and oxaliplatin (mFOLFOX) chemotherapy.

Clinical evidence suggests that pemigatinib may be more effective than current treatments, but this is highly uncertain because the trial did not directly compare pemigatinib with symptom control or mFOLFOX. The results of an indirect comparison are very uncertain.

Pemigatinib meets NICE's criteria for a life-extending treatment at the end of life. But the most likely cost-effectiveness estimates are higher than what NICE considers a cost-effective use of NHS resources. Pemigatinib does not meet the criteria for inclusion in the Cancer Drugs Fund. So pemigatinib is not recommended.